Risk Factor Analysis of Adverse Effects of Kanamycin and Capreomycin on Kidney Function in Multidrug-Resistant TB Patients
Open Access
- 2 August 2023
- journal article
- research article
- Published by Universitas Airlangga in Jurnal Farmasi dan Ilmu Kefarmasian Indonesia
- Vol. 10 (2) , 202-209
Abstract
Background: Multidrug-Resistant TB treatment's high side effects and long duration are barriers to successful TB therapy. Various side effects such as age, gender, body weight, comorbidities, and drug dose can cause severe side effects, including impaired renal function (nephrotoxic). Objectives: This study aimed to analyze the risk factors of side effects of the failure of kanamycin and capreomycin therapy that can cause impaired renal function in Multidrug-Resistant TB patients. Methods: Data were collected retrospectively by searching and recording the medical records of Multidrug-Resistant TB patients at the Multidrug-Resistant TB Polyclinic. There were 183 patients at Dr Soetomo Hospital who met the inclusion criteria. Results: There was a significant relationship between gender in the kanamycin group and the appearance of side effects of renal impairment (p= 0.035). There was no effect of age, comorbid diseases, body weight, and dose of drug administration on the side effects of kanamycin and capreomycin in treating Multidrug-Resistant TB on impaired renal function (nephrotoxic). However, nephrotoxic side effects in elderly patients were more common in the kanamycin group (p=0.001). Conclusion: Gender affects the side effects of kanamycin and capreomycin in treating Multidrug-Resistant TB in nephrotoxic patients. In addition, stricter supervision of the use of kanamycin in elderly patients (>40 years) to minimize the incidence of side effects of impaired renal function in the treatment of Multidrug-Resistant TB.Keywords
This publication has 18 references indexed in Scilit:
- Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy studyThe Lancet Infectious Diseases, 2022
- Factors influencing the length of hospital stay during the intensive phase of multidrug-resistant tuberculosis treatment at Amhara regional state hospitals, Ethiopia: a retrospective follow up studyBMC Public Health, 2020
- Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort studyBMC Pharmacology and Toxicology, 2019
- Risk factors for multidrug‐resistant tuberculosis in northwest Ethiopia: A case–control studyTransboundary and Emerging Diseases, 2019
- Comparison of Serum Potassium, MagnEsium, and Calcium Levels between Kanamycin and Capreomycin-BASEd Regimen-Treated MultiDrug-Resistant TuBerculosis Patients in Bandung (CEASE MDR-TB): A Retrospective Cohort StudyInternational Journal of Microbiology, 2019
- Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experienceJournal for ImmunoTherapy of Cancer, 2019
- Occurrence, Management, and Risk Factors for Adverse Drug Reactions in Multidrug Resistant Tuberculosis PatientsAmerican Journal of Therapeutics, 2018
- Hearing loss with kanamycin treatment for multidrug-resistant tuberculosis in BangladeshEuropean Respiratory Journal, 2018
- Diabetes is Associated With Severe Adverse Events in Multidrug-Resistant TuberculosisArchivos de Bronconeumología, 2017
- Multidrug Resistant Tuberculosis (MDR-TB): Tinjauan Epidemiologi dan Faktor Risiko Efek Samping Obat Anti TuberkulosisMajalah Kedokteran Bandung, 2014